The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Atyr Pharma Inc. | Common Stock | 002120103 | 457 | 130,571 | SH | SOLE | 130,571 | 0 | 0 | ||
Cardlytics, Inc. | Common Stock | 14161W105 | 50,550 | 1,508,065 | SH | SOLE | 1,508,065 | 0 | 0 | ||
Dare Bioscience, Inc. | Common Stock | 23666P101 | 254 | 326,243 | SH | SOLE | 326,243 | 0 | 0 | ||
Fate Therapeutics, Inc. | Common Stock | 31189P102 | 17,701 | 1,139,783 | SH | SOLE | 1,139,783 | 0 | 0 | ||
Genocea Biosciences, Inc. | Common Stock | 372427401 | 714 | 246,078 | SH | SOLE | 246,078 | 0 | 0 | ||
Kala Pharmaceuticals, Inc. | Common Stock | 483119103 | 4,555 | 1,197,032 | SH | SOLE | 1,197,032 | 0 | 0 | ||
Neuronetics, Inc. | Common Stock | 64131A105 | 6,088 | 732,583 | SH | SOLE | 732,583 | 0 | 0 | ||
Pulmatrix, Inc. | Common Stock | 74584P202 | 294 | 359,439 | SH | SOLE | 359,439 | 0 | 0 | ||
Selecta Biosciences, Inc. | Common Stock | 816212104 | 4,854 | 2,773,479 | SH | SOLE | 2,773,479 | 0 | 0 | ||
x4 Pharmaceuticals Inc. | Common Stock | 98420x103 | 3,959 | 311,492 | SH | SOLE | 311,492 | 0 | 0 | ||
Phreesia, Inc. | Common Stock | 71948P106 | 86,566 | 3,571,213 | SH | SOLE | 3,571,213 | 0 | 0 |